Author: Customer Service

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference presentation on Wednesday, June 3rd, 2026, at 12:15 p.m. ET; and Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat on Wednesday, June 10th, 2026, at 10:00 a.m. ETLive webcasts can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com. Replays will also be available following the events. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current...

STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Details of the event are as follows: Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company’s website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium...

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying...

Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance, as reflected by the Pro-C3/CTX-III ratio, with associated improvements in Baveno portal hypertension risk categoryPoster presentation on risk reduction in clinically significant portal hypertension designated a TOP Poster at EASL 2026 — selected among the best abstracts in the Portal Hypertension session and displayed throughout all four days of the congressBelapectin 2 mg/kg produced a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04), with significantly fewer patients experiencing worsening of liver stiffness as measured by FibroScan®NORCROSS, Ga., May 27, 2026 (GLOBE...

The Competition Authority has approved Tallinna Vesi’s application to harmonise the price of water service for private and business customers with effect from 1 July 2026. The change follows from the obligation imposed by law to offer the same prices to private and business customers, and it reflects the need for continued investment in clean drinking water, environmental protection, and maintaining service continuity.  According to Taavi Gröön, Tallinna Vesi’s Chief Financial Officer, the company has been working towards harmonising prices for private and business customers within the limits set out in the Public Water Supply and Sewerage Act since 2010, a process that has now been completed. Under the implementing provisions of the Act, water suppliers that have set different prices for private and business customers must bring...

Key PointsLive Oak Bank is highlighting the first-year impact of a five-year, $1 million commitment to The Forward Fund, supporting the organization’s pay-it-forward financing model for career training and upskilling in North Carolina. In its first year, the program issued $2.3 million in loans to over 270 individuals.WILMINGTON, N.C., May 27, 2026 (GLOBE NEWSWIRE) — Live Oak Bank announced a $1 million grant to The Forward Fund, North Carolina’s first pay-it-forward fund dedicated to financing career training and upskilling for working adults. The grant launched in 2025 and will be paid over five years. The Forward Fund offers zero-percent interest financing for training, living expenses, and support services in high-demand fields, including commercial driver’s license (CDL), basic law enforcement training, registered...

Company Advances Flagship Carbonatite Target as Initial Drill Core Is Submitted for Assay CALGARY, Alberta, May 27, 2026 (GLOBE NEWSWIRE) — Pan American Energy Corp. (CSE: PNRG | OTC: PAANF | FRA: SS6) (“Pan American” or the “Company”) is pleased to report that detailed geological logging and core sampling from its 2026 diamond drilling program at the Tharsis Project in the Northwest Territories have now been completed, and samples have been submitted to ALS for geochemical analysis. The 2026 drill campaign marked the first drill testing of the Squalus Lake Alkaline Complex (“SLAC”), with 464.5 metres of diamond drilling completed across five boreholes, including TH26-001 (107 m), TH26-002 (98 m), TH26-003 (153.5 m), TH26-004 (44 m), and TH26-004A (62 m). The program focused on the northern intrusive center, a priority target area...

MISSISSAUGA, Ontario, May 27, 2026 (GLOBE NEWSWIRE) — Bird Construction Inc. (“Bird” or the “Company”) (TSX: BDT) today announced that it has launched an offering (the “Offering”) of senior notes (the “Notes”) and entered into an amendment to its existing credit agreement which will take effect when the Offering closes. Bird intends to use the net proceeds from the Offering to repay all of Bird’s outstanding debt under its non-revolving term loan facility (approximately $204 million) and to apply any balance for general corporate purposes, which may include repayment of amounts drawn under revolving credit facilities or funding future acquisitions. The Notes will be unsubordinated obligations of Bird and will be guaranteed on an unsubordinated basis by each of Bird’s subsidiaries that guarantee Bird’s obligations under its credit...